The Allelic Expression of RNA Editing Gene ADARB1 in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization

• DOI: 10.2147/pgpm.s402115
• Publication Date: 2023-03-17T11:25:05Z
• Authors: Jiajia Zeng; Linyu Han; Teng Wang; Linying Huang; Yanxiu Zheng; Nasha Zhang; Ziqiang Li; Ming Yang
• Keywords: ADAR

Introduction: Transarterial chemoembolization (TACE) is the commonly used therapy of unresectable hepatocellular carcinoma (HCC), though prognosis different TACE-treated HCC patients varies, which may be due to heterogeneity tumors caused by genetic variants and epigenetic changes such as RNA editing. There dysregulated adenosine-to-inosine (A-to-I) editing in RNA-edited genes are involved process. It remains unclear how affect cases treated TACE. Methods: In this study, we examined 28 potentially functional single-nucleotide polymorphisms (SNPs) four ( ADARB1, ADAR, ADARB2 AIMP2 ) two independent TACE patient cohorts. Results: We found that ADARB1 rs1051367 rs2253763 were markedly associated with who received both cells, C-to-T change 3'-untranslated region attenuated its binding miR-542-3p allele-specifically elevated levels. Consistent this, carrying C allele showed reduced expression cancer tissues notably shorter survival after comparison individuals T allele. Ectopic profoundly enhanced efficacy oxaliplatin, one common chemotherapeutic drugs. Discussion: Our findings highlighted value prognostic markers for patients. Notably, our revealed targeting enzyme a promising therapeutic strategy combination cases. Keywords: editing, carcinoma, polymorphism, gene expression, drug sensitivity